Italia markets closed

Nanobiotix S.A. (0QAV.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
3,8100+0,1150 (+3,11%)
Alla chiusura: 05:51PM GMT
Schermo intero
Caricamento grafico interattivo in corso...
  • GlobeNewswire

    Voting Rights and Shares Capital of the Company

    In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Paris, France, December 8, 2022Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights, theoretical

  • GlobeNewswire

    NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference

    PARIS and CAMBRIDGE, Mass., Nov. 15, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in a virtual fireside chat at the 5th annual Evercore ISI HealthCONx Conference on Thursda

  • GlobeNewswire

    NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic Cancer

    Data show that radiotherapy-activated NBTXR3 was feasible and well tolerated in the complete dose escalation part of a Study 2019-1001, a phase 1 evaluation of NBTXR3 for patients with locally advanced pancreatic adenocarcinomaThe recommended phase 2 dose for radiotherapy-activated NBTXR3 in pancreatic cancer was established at 42% of gross tumor volume and the dose expansion part of the study is ongoing in the United StatesThe company expects to report safety and early efficacy data from the es